Tasman Health News
Trial News – Checkmate 9ER (Nivolumab & Cabozantinib) Press Release
A Phase 3, Randomized, Open-Label Study of Nivolumab Combined with Cabozantinib versus Sunitinib in Participants with Previously Untreated Advanced or Metastatic Renal Cell Carcinoma. The [...]
Bushfire Appeal
Thanks to all our patients and staff who donated to our Bushfire Appeal very happy to announce we raised $391.45 and Tasman Health Care will [...]
Have you been diagnosed with Stage IIB or IIC Melanoma?
Adjuvant Therapy With Pembrolizumab Versus Placebo in Resected High-risk Stage II Melanoma: A Randomized, Double-blind Phase 3 Study (KEYNOTE-716) You may qualify for a clinical [...]
Gastric Cancer Trial Now Open at Tasman Health Care
Gastric Cancer Trial Now Open at Tasman Health Care Tasman Health Care is pleased to announce that recruitment is open for the CA209-649 study. This [...]
FDA Accepts sBLA for Nivolumab Plus Ipilimumab
FDA Accepts sBLA for Nivolumab Plus Ipilimumab in Previously Treated MSI-H or dMMR Metastatic Colorectal Cancer On March 27, the U.S. Food and Drug Administration [...]
Welcome to Tasman Health Care
Tasman Health Care is a comprehensive clinical research-focused oncology group that is committed to delivering a high standard of individual quality patient care. Please enjoy [...]